Clinical trial
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants…
NCT00408434 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00408434 |
|---|---|
| Title | Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer |
| Official title | A Phase I Dose Finding Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Patients With Advanced or Malignancies |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasm |
| Intervention type | Drug |
| Interventions | CS-7017 |
| Enrollment | 32 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Dec 7, 2006 |
| Last update posted | Oct 19, 2020 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: